Weekly Analysts’ Ratings Updates for Natera (NTRA)

Natera (NASDAQ: NTRA) has recently received a number of price target changes and ratings updates:

• 3/7/2026 – Natera was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/3/2026 – Natera had its price target lowered by Morgan Stanley from $265.00 to $250.00. They now have an “overweight” rating on the stock.
• 2/27/2026 – Natera had its price target raised by Wells Fargo & Company from $205.00 to $215.00. They now have an “equal weight” rating on the stock.
• 2/27/2026 – Natera had its price target raised by Robert W. Baird from $239.00 to $257.00. They now have an “outperform” rating on the stock.
• 1/22/2026 – Natera had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other news, CFO Michael Burkes Brophy sold 37,175 shares of Natera stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total value of $9,016,424.50. Following the completion of the sale, the chief financial officer owned 64,123 shares of the company’s stock, valued at $15,552,392.42. The trade was a 36.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Solomon Moshkevich sold 23,205 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70. Following the completion of the transaction, the insider owned 144,992 shares of the company’s stock, valued at $34,035,422.08. The trade was a 13.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 318,344 shares of company stock valued at $74,091,416. Insiders own 5.63% of the company’s stock.

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.